Navigation Links
Costs of Eradicating Poliomyelitis Now Are Much Lower Than Trying,to Control It Later

LONDON, April 12, 2007--The costs of eradicating poliomyelitis from the remaining infected countries, while high in the short term, are much lower than the long term costs of trying to control infections without eradication. And a recently developed monovalent vaccine is almost three times more effective against type 1 poliomyelitis than an existing trivalent vaccine. These are the findings of two Articles published Online and in an upcoming issue of The Lancet.

Both Articles look at the success of the Global Polio Eradication Initiative (GPEI), started in 1988 by the World Health Organisation, which has reduced the global incidence of poliomyelitis by 99%.

In the first, Professor Kimberly Thompson and Dr Radboud Duintjer Tebbens of Harvard School of Public Health, Boston, USA used a dynamic modelling technique based on current wild poliovirus endemic areas of India. The results show the importance of maintaining and increasing the immunisation intensity to complete eradication.

They find that even small decreases in this intensity could lead to large outbreaks—and state that more short term funds are needed than are currently being spent.

The authors conclude: "Worldwide eradication of polioviruses is likely to yield substantial health and financial benefits, provided we finish the job."

In the second paper, Dr Nicholas Grassly and of the Department of Infectious Disease Epidemiology, Imperial College, London, UK and Dr Bruce Aylward, of the World Health Organisation, Switzerland and colleagues did a study of the efficacy of the monovalent oral type 1 poliovirus vaccine (moPV1).

This vaccine was developed in 2005 to tackle persistent poliovirus transmission in the last remaining infected countries—India, Pakistan, Afghanistan, Nigeria, Niger, and Egypt.

pressoffice@lancet.com

Please mention The Lancet as the source of this material

Issued by Tim Duffy, Acting North American Editorial and Press Coordinator, The Lancet
Press pressoffice@lancet.com Telephone: +44 (0)20 7424 4949/4249

A case-control study of more than 2000 people in India estimated the efficacy of mOPV1 to be 30% per dose against type 1 paralytic poliomyelitis in the Uttar Pradesh region, compared with 11% for the standard trivalent oral vaccine.

Between 76–82% of children aged 0–23 months in Uttar Pradesh were estimated to be protected by vaccination against type 1 poliovirus at the end of 2006 (after repeated rounds of vaccination with mOPV1)—compared with 59% at the end of 2004, prior to the introduction of mOPV1.

The authors conclude: "Achieving high coverage with the new vaccine in areas of persistent poliovirus transmission should substantially improve the probability of rapidly eliminating transmission of the disease."

In an accompanying Comment, Professor Paul Fine and Dr Ulla Griffiths, of the London School of Hygiene and Tropical Medicine, said: "The demonstration of superior effectiveness of mOPV1 vaccine adds to the evidence that termination of wild poliovirus transmission is technically feasible, given enough time, continued funding, political stability, and continued political support in the affected areas of the world."

Professor Kimberly M Thompson, Harvard School of Public Health, Boston, USA. T) +1 617 432 4285

Dr Bruce Aylward, Global Polio Eradication Initiative, World Health Organisation, Switzerland. T) +41 79 217 3438

Comment Professor Paul Fine, London School of Hygiene and Tropical Medicine, London, UK. T) +44 (0) 20 7927 2219

kimt@hsph.harvard.edu

aylwardb@who.int

Paul.Fine@lshtm.ac.uk


'"/>




Related medicine technology :

1. Point of Care Strep Tests Speed Treatment, Lower Costs
2. Lipitor Significantly Lowered Hospitalization Costs for Patients with Heart Disease, Two New Analyses Show
3. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
4. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
5. Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology Shown to Significantly Lower Instances of Severe Retinopathy of Prematurity in Extremely Low Birth Weight Infants
6. Data Presented at ASH Demonstrate Nebivolol Lowers Blood Pressure as Long-Term Monotherapy and in Combination Therapy
7. New Data from the US and Japan Support: No Established Causal Link Between Neuropsychiatric Symptoms and Treatment with Tamiflu US Databases Indicate Psychiatric Symptoms Lower in Influenza Patients Taking Tamiflu Versus Those Not Taking Tamiflu
8. Framingham Study Shows Parents Who Live Long Pass On Lower Risk of Cardiovascular Disease
9. Controlling the Spread of Healthcare Associated Methicillin Resistant Staphylococcus aureus Requires Active Surveillance
10. Tight Glycemic Control in the ICU
11. New Quality Control Systems for Every Laboratory Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):